Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 18 of 18
New CAR T cells on the horizon
Marcela V Maus
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 8:00 AM-9:45 AM
New targets and technologies for CAR-T
Michael Hudecek
University Hospital Wurzburg, Wurzburg, Germany
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 8:00 AM-9:45 AM
Engineering CAR T Cells to Overcome Resistance
Crystal L Mackall
Stanford University School of Medicine, Stanford, California, Stanford, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 8:00 AM-9:45 AM
Targeted Protein Degradation as a new Approach to Cancer Drugs
Nathanael S Gray
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 10:00 AM-11:45 AM
Exploiting E3 ligases for target validation and drug discovery: What have we learnt so far?
Rajesh Chopra
The Institute of Cancer Research, London, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 10:00 AM-11:45 AM
The zinc-finger degrome
Nicolas H. Thoma
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 10:00 AM-11:45 AM
A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor
Mark R. Kelley
Indiana University School of Medicine, Indianapolis, IN, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 11:50 AM-12:20 PM
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M Schram
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 11:50 AM-12:20 PM
A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Rebecca S Heist
Massachusetts General Hospital, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 11:50 AM-12:20 PM
CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno
START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Maximizing the potential of bispecific antibodies for cancer drug development
Paul W H I Parren
Leiden University Medical Center and Lava Therapeutics, Utrecht, Netherlands
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Rational cancer & immune cell therapy combinations a functional genomics approach
Daniel Peeper
Netherlands Cancer Institute, Amsterdam, Netherlands
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Discovery and development of HIF-2a inhibitors for the treatment of clear cell renal cell carcinoma
Eli Wallace
Peloton Therapeutics, Inc., Dallas, TX, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Targeting the opposing roles of IFN for cancer immunotherapy
Andy J. Minn
Abramson Family Cancer Research Institute, Philadelphia, PA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Functional genomics approaches to the discovery of paralog dependencies in cancer
William R Sellers
Broad Institute of MIT and Harvard, Cambridge, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Functional genomics approaches to identify targetable dependencies in cancer cells
Mathew Garnett
Wellcome Sanger Institute, Cambridge, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
Discovering regulators of the immune response to cancer using functional genomics
W Nicholas Haining
Merck & Company, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 18 of 18